Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Allergy
Published in: Clinical and Translational Allergy 1/2013

Open Access 01-12-2013 | Research

Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey

Authors: Mark Small, James Piercy, Pascal Demoly, Helen Marsden

Published in: Clinical and Translational Allergy | Issue 1/2013

Login to get access

Abstract

Background

Allergic Rhinitis is an inflammatory disease which is characterised by burdensome nasal and/or ocular symptoms. This study aimed to assess the impact of symptoms (number of symptom-free days (SFD) and Quality of Life (QoL)) in patients with Seasonal Allergic Rhinitis (SAR) being treated with fluticasone furoate (FF), mometasone furoate (MF) or fluticasone propionate (FP).

Methods

In a cross-sectional, non-interventional, cohort analysis, primary care physicians and allergy specialists in France, Germany, and Spain were recruited via telephone interviews. Each physician prospectively recruited 4 SAR patients - 2 receiving FF, 1 receiving MF and 1 receiving FP - during June 2009. Patients answered questions on symptoms and completed questionnaires on QoL (mini-rhinoconjunctivitis Quality of Life Questionnaire, RQLQ) and burden of illness (Pittsburgh Sleep Quality Index).

Results

A total of 540 patients were recruited during June 2009. 88 patients were subsequently found to be ineligible and excluded from the analyses. In the 4 weeks prior to assessment, patients reported a mean of 14.58 (±8.42) SFD. Patients receiving FF had more SFD (mean 15.45 ±8.29) than patients receiving MF (adjusted mean difference -1.22, 95% Confidence Interval (CI) [-3.16 to 0.72], p=0.434) or FP (adjusted mean difference -1.95, 95% CI [-3.87 to -0.03], p=0.092), although statistical significance was not achieved. The mean RQLQ score was 1.54 (±1.06). Patients receiving FF had a better quality of life in the previous week (mini-RQLQ score: mean 1.42, ±1.04) than patients receiving MF (adjusted mean difference 0.28, 95% CI [0.03 to 0.52], p=0.052) or FP (adjusted mean difference 0.18, 95% CI [-0.05 to 0.41], p=0.244). Again, none of these results achieved statistical significance.

Conclusions

At the height of the allergy season, patients with SAR suffer symptoms approximately 50% of the time, and report an impact on their QoL. No significant differences were observed between FF, FP and MF related to SFD or QoL.

Trial registration

ClinicalTrials.gov identifier: NCT01199757
Appendix
Available only for authorised users
Literature
1.
Bauchau V, Durham SR: Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004, 24: 758-764. 10.1183/09031936.04.00013904.CrossRefPubMed
2.
Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC: A survey of the burden of AR in Europe. Allergy. 2007, 62 (Suppl 85): 17-25.CrossRefPubMed
3.
Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L, Yelin EH: The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol. 2001, 54: 610-618. 10.1016/S0895-4356(00)00349-8.CrossRefPubMed
4.
Vuurman EF, van Veggel LM, Sanders RL, Muntjewerff ND, O’Hanlon JF: Effects of semprex-D and diphenhydramine on learning in young adults with SAR. Ann Allergy Asthma Immunol. 1996, 76: 247-252. 10.1016/S1081-1206(10)63435-7.CrossRefPubMed
5.
Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: SAR is associated with detrimental effect on examination performance in UK teenagers. J Allergy Clin Immunol. 2007, 120: 381-387. 10.1016/j.jaci.2007.03.034.CrossRefPubMed
6.
Meltzer EO, Nathan RA, Selner JC, Storms W: QoL and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol. 1997, 99: S815-S819. 10.1016/S0091-6749(97)80041-3.CrossRef
7.
Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F: QoL in AR and asthma. A population-based study of young adults. Am J Respir Crit Care Med. 2000, 162: 1391-1396. 10.1164/ajrccm.162.4.9912033.CrossRefPubMed
8.
van Cauwenberge P, Van Hoecke H, Kardos P, Price D, Waserman S: Current burden of AR among primary care practitioners and its impact on patient management. Prim Care Respir J. 2009, 18: 27-33. 10.3132/pcrj.2008.00042.CrossRefPubMed
9.
Virchow JC, Kay S, Demoly P, Mullol J, Canonica W, Higgins V: Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ. 2011, 14: 305-314. 10.3111/13696998.2011.576039.CrossRefPubMed
10.
Jacobs R, Martin B, Hampel F, Toler W, Ellsworth A, Philpot E: Effectiveness of fluticasone furoate 110 μg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin. 2009, 25: 1393-1401. 10.1185/03007990902890512.CrossRefPubMed
11.
Bielory L: Allergic Conjunctivitis and the impact of Allergic Rhinitis. Curr Allergy Asthma Rep. 2010, 10: 122-134. 10.1007/s11882-010-0087-1.CrossRefPubMed
12.
DeWester J, Philpot EE, Westlund RE, Cook CK, Rickard KA: The efficacy of intranasal Fluticasone Propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy and Asthma Proc. 2003, 24: 331-337.PubMed
13.
Bartra J, Mullol J, Montoro J, Jauregui I, del Cuvillo A, Davila I, Ferrer M, Sastre J, Valero A: Effect of bilsatime upon the ocular symptoms of allergic rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2011, 21 (Suppl 3): 24-33.PubMed
14.
Lightman S, Scadding GK: Should intranasal corticosteroids be used for the treatment of ocular symptoms of Allergic Rhinoconjunctivitis? A review of the efficacy and safety profile. Int Arch Allergy Immunol. 2012, 158: 317-325. 10.1159/000333100.CrossRefPubMed
15.
Hellings PW, Dobbels F, Denhaerynck K, Piessens M, Ceuppens JL, De Geest S: Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy. 2012, 2: 9-10.1186/2045-7022-2-9.PubMedCentralCrossRefPubMed
16.
Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH, Lanier BQ, Penna P and the American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis: Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance and satisfaction. Otolaryngol Head Neck Surg. 2007, 136: S107-S124. 10.1016/j.otohns.2007.02.031.CrossRefPubMed
17.
Given JT, Cheema AS, Dreykluft T: Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults. Am J Rhinol Allergy. 2010, 24: 444-450. 10.2500/ajra.2010.24.3534.CrossRefPubMed
18.
Meltzer EO, Munafo DA, Chung W, Gopalan G, Varghese ST: Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. Ann Allergy Asthma Immunol. 2010, 105: 65-74. 10.1016/j.anai.2010.04.020.CrossRefPubMed
19.
Scichilone N, Arrigo R, Paterno A, Santagata R, Impellitteri S, Braido F, Baiardini I, Battaglia S, Canonica GW, Bellia V: The effect of intranasal corticosteroids on asthma control and quality of life in allergic rhinitis with mild asthma. J Asthma. 2011, 48: 41-47. 10.3109/02770903.2010.528821.CrossRefPubMed
20.
Rodrigo GJ, Neffen H: Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. Clin Exp Allergy. 2011, 41: 160-170. 10.1111/j.1365-2222.2010.03654.x.CrossRefPubMed
21.
Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J: Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy. 2002, 57: 586-591. 10.1034/j.1398-9995.2002.03228.x.CrossRefPubMed
22.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, Van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet L-P, Bousquet P-J, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, Van Wijk RG, Kalayci O, Kaliner MA, Kim Y-Y, Kowalski ML: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008, 63 (suppl 86): 8-160.CrossRefPubMed
23.
Juniper EF, Thompson AK, Ferrie PJ, Roberts JN: Development and calibration of the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy. 2000, 30: 132-140. 10.1046/j.1365-2222.2000.00668.x.CrossRefPubMed
24.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Research. 1989, 28: 193-213. 10.1016/0165-1781(89)90047-4.CrossRefPubMed
25.
Reilly MC, Tanner A, Meltzer EO: Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest. 1996, 11: 278-288. 10.2165/00044011-199611050-00004.CrossRef
26.
Scadding G, Williams A: The burden of allergic rhinitis as reported by UK patients compared with their doctors. Rhinology. 2008, 46: 99-106.PubMed
27.
Villa E, Magnoni MS, Micheli D, Canonica GW: A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother. 2011, 12: 2107-2117. 10.1517/14656566.2011.600688.CrossRefPubMed
28.
Okubo K, Nakashima M, Miyake N, Komatsubara M, Okuda M: Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis. Allergy Asthma Proc. 2009, 30: 84-94. 10.2500/aap.2009.30.3182.CrossRefPubMed
29.
Meltzer EO, Andrews C, Journeay GE, Lim J, Prillaman BA, Garris C, Philpot E: Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol. 2010, 104: 331-338. 10.1016/j.anai.2010.02.010.CrossRefPubMed
30.
Garris C, Shah M, D'Souza A, Stanford R: Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms: Retrospective cohort analysis of pharmacy claims data. Clin Drug Invest. 2009, 29: 515-526. 10.2165/00044011-200929080-00002.CrossRef
Metadata
Title
Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey
Authors
Mark Small
James Piercy
Pascal Demoly
Helen Marsden
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2013
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/2045-7022-3-33

Other articles of this Issue 1/2013

Clinical and Translational Allergy 1/2013 Go to the issue

Review

Diagnosis and management of non-IgE-mediated cow’s milk allergy in infancy - a UK primary care practical guide

Research

Grass pollen allergy in children and adolescents-symptoms, health related quality of life and the value of pollen prognosis

Research

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells

Review

Gene expression analysis in allergology: the prediction of Hymenoptera venom allergy severity and treatment efficacy

Review

Management of hypersensivity pneumonitis

Brief communication

The protein structure determines the sensitizing capacity of Brazil nut 2S albumin (Ber e1) in a rat food allergy model